Edgar Filing: MACROGENICS INC - Form 10-Q

MACROGENICS INC

Form 10-Q

May 01, 2019

FALSEMarch 31, 20192019Q1Large Accelerated FilerFALSEFALSEMACROGENICS

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY

REPORT

PURSUANT

TO SECTION

13 OR 15(d) OF

THE

SECURITIES

EXCHANGE

ACT OF 1934

For the quarterly period ended March 31, 2019

OR

TRANSITION

REPORT

PURSUANT

TO SECTION

13 OR 15(d) OF

THE

SECURITIES

EXCHANGE

ACT OF 1934

For the transition period from _____ to ____

Commission File Number: 001-36112

MACROGENICS, INC.

(Exact name of registrant as specified in its charter)

Delaware 06-1591613

(State or other

(I.R.S.

jurisdiction of

Employer -

incorporation

Identification

organization)

No.)

9704 Medical

9/04 Medical

Center Drive

20850

Rockville, Maryland

(Zip code)

Edgar Filing: MACROGENICS INC - Form 10-Q

(Address of principal executive offices)

301-251-5172

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "accelerated filer," "large accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Non-accelerated

Smaller reporting company

Emerging growth

company

filer

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of April 26, 2019, the number of outstanding shares of the registrant's common stock, par value \$0.01 per share, was 48,805,620 shares.

TABLE OF CONTENTS

PART FINANCIAL

I. <u>INFORMATION</u>

Item 1. Financial Statements

Consolidated

Balance Sheets at

March 31, 2019

(unaudited) and

December 31, 2018

Consolidated

Statements of

Operations and

Comprehensive

Loss for the three

months ended

March 31, 2019 and

March 31, 2018

(unaudited)

Consolidated

Statements of

Stockholders' Equity

for the three months

ended March 31,

2019 and March 31,

2018 (unaudited)

Consolidated

Statements of Cash

Flows for the three

months ended

March 31, 2019 and

March 31, 2018

(unaudited)

Notes to

Consolidated

Financial

Statements

(unaudited)

Management's

Discussion and

Item 2. Analysis of

Financial Condition

and Results of

Operations

Item 3.